DR. MICHAEL YOUNGJUN CHOI, M.D.
Osteopathic Medicine at Health Sciences Dr, La Jolla, CA

License number

California A100104

Professional information

Associate Director, Program Management At Shire Regenerative Medicine

Position:

Associate Director, Program Management at Shire Pharmaceuticals

Location:

Greater San Diego Area

Industry:

Biotechnology

Work:

Shire Pharmaceuticals - La Jolla, CA since Nov 2012 - Associate Director, Program Management Illumina - Greater San Diego Area Apr 2011 - Nov 2012 - Manager, Corporate Planning Biogen Idec Jan 2007 - Jan 2011 - Program Manager, Program and Alliance Management Piffany, Inc. 2005 - May 2008 - Founder, CEO Biogen Idec Apr 2005 - Jan 2007 - Project Manager, Research Operations and Portfolio Planning Biogen Idec Jul 2002 - Apr 2005 - Associate Scientist

Education:

University of California, San Diego - The Rady School of Management 2008 - 2010
M.B.A., Strategy and Entrepeneurship Massachusetts Institute of Technology 2000 - 2002
MS, Organic Chemistry University of Illinois Urbana Champaign 1996 - 2000
BS, Chemistry Illinois Mathematics and Science Academy 1993 - 1996

Skills:

Process Simulation, Project Management, Strategic Alliances, Change Management, Program Management, Drug Discovery, Drug Development, Process Improvement, FDA, CRO, Business Development, Clinical Development, Cross-functional Team Leadership, Strategy, Oncology

Honor & Awards:

Finalist at the MIT $100K Entrepeneurship Competition (Piffany) (2006) 3rd Place at the Boston University $25K Business Plan Competition (specialized chemicals)(2009)

Business Analyst Intern At Bainbridge

Position:

Business Analyst Intern at Bainbridge, Vice President of Finance at Delta Sigma Pi - Omicron Sigma Chapter

Location:

La Jolla, California

Industry:

Banking

Work:

Bainbridge since Jun 2013 - Business Analyst Intern Delta Sigma Pi - Omicron Sigma Chapter since May 2013 - Vice President of Finance Bainbridge May 2013 - Jun 2013 - Foreign Language Business Analyst Intern Win Holdings, Inc. Oct 2010 - Feb 2012 - CFO Assistant Glen Property, Inc. Aug 2010 - Dec 2010 - Receptionist

Education:

University of California, San Diego 2012 - 2014
Bachelor of Arts (BA), Economics Santa Monica College 2010 - 2012

Hematology/Oncology Fellow At Uc San Diego Medical Center

Position:

Hematology/Oncology Fellow at UCSD

Location:

Greater San Diego Area

Industry:

Medical Practice

Work:

UCSD since 2009 - Hematology/Oncology Fellow

Education:

University of Southern California 2001 - 2005
MD

Michael Youngjun Choi, La Jolla CA

Specialties:

Internist

Address:

Moores Cancer Ctr, La Jolla, CA 92093

Education:

Doctor of Medicine

Board certifications:

American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine), American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)

Michael Youngjun Choi, La Jolla CA

Specialties:

Internal Medicine, Hematology, Medical Oncology

Work:

Urgentcare San Diego Thornton Hospital
9300 Campus Point Dr, La Jolla, CA 92037 Urgentcare San Diego Moores Cancer Center
3855 Health Sciences Dr, La Jolla, CA 92093 UC San Diego Health System
200 W Arbor Dr, San Diego, CA 92103

Education:

University of Southern California(2005)

Dr. Michael Y Choi, La Jolla CA - MD (Doctor of Medicine)

Specialties:

Hematology, Medical Oncology, Oncology

Address:

UCSD Moores Cancer Center
3855 Health Sciences Dr STE 1102, La Jolla 92093
(858) 822-6100 (Phone)

Certifications:

Hematology, 2012, Internal Medicine, 2008, Medical Oncology, 2012

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
University of Southern California / Keck School of Medicine
Graduated: 2005

Substituted Pyrazalones

US Patent:

2010005, Mar 4, 2010

Filed:

Nov 21, 2006

Appl. No.:

12/085380

Inventors:

Mary Beth Carter - Lawrence KS, US
Claudio Chuaqui - Arlington MA, US
Kevin Guckian - Marlborough MA, US
Edward Lin - Chesnut Hill MA, US
Michael J. Choi - San Diego CA, US
Zhan Deng - Winchester MA, US
Lihong Sun - Lexington MA, US

International Classification:

A61K 31/498, C07D 403/02, C07D 401/14, C07D 409/14, C07D 403/12, C07D 417/14, C07D 413/14, A61K 31/541, A61K 31/5377, A61P 43/00, A61P 35/00, A61P 9/00, A61P 9/12

US Classification:

5142282, 544353, 544 581, 544116, 514249, 5142348

Abstract:

The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.